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 Neurodegenerative diseases including Alzheimer’s 
disease (AD) and frontotemporal dementia (FTD) are the 
most frequent cause of dementia in our ageing society. 
These disorders are characterized by posttranslationally 
modified amyloidogenic proteins, such as amyloid   -
peptide (A  ) in AD and tau in AD and FTD, which form 
neurotoxic oligomers and are finally deposited as insolu-
ble amyloid fibers in senile plaques or tangles  [1–3] .
 Neurodegenerative diseases with deposition of insol-
uble tau protein are now commonly termed tauopathies. 
The tau protein is an important target for drug develop-
ment, since its pathological alterations correlate with
disease progression and memory loss in AD and other 
tauopathies  [4] . Moreover, tau suppression improves 
memory function in transgenic FTD models  [5] . Further-
more, mutations in the tau gene, such as the Tau-P301L 
mutation, have been identified in patients with a geneti-
cally inherited form of autosomal dominant FTD  [6] . 
Among the first pathological alterations of tau is its 
pathologic phosphorylation at multiple residues  [2] . Sub-
sequently, the hyperphosphorylated tau species become 
insoluble and form paired helical filaments, which are 
finally deposited in the cell bodies of neurons as neurofi-
brillary tangles (NFT). The biochemical and pathological 
properties of tau have been extensively studied both in 
vitro and in vivo. Over the last decade, several tau trans-
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 Abstract 
 Our ageing society is confronted with a dramatic increase in 
patients suffering from tauopathies such as Alzheimer’s dis-
ease, frontotemporal dementia and others. Typical neuro-
pathological lesions including tangles composed of hyper-
phosphorylated tau protein as well as severe neuronal cell 
death characterize these disorders. No mechanism-based 
cures are available at present. Genetically modified animals 
are invaluable models to understand the molecular disease 
mechanisms and to screen for modifying compounds. We 
recently introduced tau-transgenic zebrafish as a novel 
model for tauopathies. Our model allows recapitulating key 
pathological features of tauopathies within an extremely 
short time. Moreover, life imaging of tau-dependent neuro-
nal cell death was performed for the very first time. This 
demonstrated tau-dependent neuronal cell loss indepen-
dent of tangle formation. Finally, we exemplified that the ze-
brafish frontotemporal dementia model can be used to 
screen for drugs that prevent abnormal tau phosphorylation 
and neuronal cell death. 
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genic animal models have been developed. Invertebrates 
such as worms and flies and vertebrates like mice have 
been used to understand pathogenic mechanisms [for de-
tailed reviews, see  7, 8 ]. In addition, chemical modifiers 
of the disease which could be further explored to develop 
novel treatment approaches have been investigated in 
these animals. Invertebrate systems offer experimental 
advantages, including low costs, small size, excellent ge-
netic tractability, a simple and rapidly developing ner-
vous system and a short life span. However, the evolution-
ary and morphological distance between invertebrates 
and humans makes the direct translation of experimental 
results rather difficult and unreliable. Therefore, neuro-
toxic mechanisms evoked by amyloidogenic proteins may 
be more faithfully reproduced in vertebrate brains. For 
this reason, transgenic mice have been the major species 
used for modeling AD and FTD.
 The generation of these mouse models began with the 
expression of wild-type tau, which led to its pathologic 
phosphorylation, but not filament formation. This key 
feature of tauopathies was only reproduced upon express-
ing tau with familial FTD-associated tau mutations. Sub-
sequently, the FTD-like phenotypes could be further en-
hanced by the addition of A  , indicating cross-talk be-
tween A  and tau aggregation. Finally, coexpression of 
mutant tau with the Swedish mutation of the   -amyloid 
precursor protein as well as the familial AD-associated 
presenilin 1 M146V mutation, led to the enhanced for-
mation of NFTs, again supporting the amyloid cascade 
hypothesis. However, tau seems to be the primary media-
tor of toxicity and memory loss, since inhibition of tau 
expression in such triple transgenic mice allowed recov-
ery of memory and a reduction in neuronal cell loss. In-
terestingly, under these conditions NFTs continued to ac-
cumulate, suggesting that soluble tau oligomers but not 
tangles may be the primary neurotoxic species  [1, 7, 8] .
 The abovementioned models greatly expanded our 
knowledge on the formation of the typical neuropathol-
ogy of AD and FTD and the pathologic misfunction of 
disease-associated genes. However, the initial steps lead-
ing to tau phosphorylation and synaptic dysfunction, 
which in humans may occur presymptomatically are still 
poorly understood in vivo. It is extremely difficult to in-
vestigate early subtle changes and disease propagation in 
living mice, since their brain is not readily accessible for 
imaging and they need a rather long time to develop dis-
ease symptoms. In addition, large-scale screening for 
anti-aggregation drugs, or neurotoxicity-ameliorating 
compounds, is not feasible in mice. Transgenic zebrafish 
larvae combine many of the advantages of invertebrate 
and vertebrate models. Their translucent body allows 
whole-body imaging of cellular and subcellular processes 
in high detail ( fig. 1 ) both in fixed animals and in vivo 
 [9] . In addition, large-scale compound screens, which are 
feasible due to the small size of the fish larvae, have al-
ready been performed  [10] . Two zebrafish models of 
tauopathies have already been described. Tomasiewicz et 
al. [11] injected cDNA constructs encoding human Tau-
GFP fusion proteins into zebrafish eggs to study tau pa-
thology. While this approach led to tau phosphorylation 
at a pathologically relevant epitope in a small number of 
neurons expressing the injected DNA, it failed to generate 
transgenic lines with stable and reproducible expression. 
In addition, tangle formation, disease progression as well 
as neuronal loss were not described. The generation of 
stable transgenic lines was first achieved by Bai et al. [12] , 
who described a human tau-transgenic fish using the ze-
brafish Enolase2 promoter. This promoter allowed ex-
pressing tau specifically in the nervous system; however, 
no signs of tau pathology were observed at larval stages 
of development. This might be due to insufficient tau pro-
tein levels, since high expression levels have been shown 
to be essential for a concentration-dependent amyloid ag-
gregation mechanism in model systems  [13] . We have 
therefore developed a Gal4-UAS-based expression sys-
tem to efficiently generate transgenic zebrafish overex-
 Fig. 1. The translucent body of zebrafish 
larvae allows imaging of cellular and sub-
cellular processes in high detail. Triple 
immuno staining of a 5-day-old tau-trans-
genic zebrafish, using antibodies against 
acetylated tubulin, showing neuronal 
projections in green, total tau in red and 
AT8-phosphorylated tau in blue. 
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pressing high levels of human Tau-P301L or other dis-
ease-associated proteins under control of the neuronal 
zebrafish HuC promoter. The Gal4-UAS system ampli-
fies gene expression by both the strong herpes simplex 
virus VP16 transcriptional activator, which is fused to 
Gal4, and the use of 14 UAS sites, to which the Gal4-VP16 
binds  [14] . The tau-transgenic fish rapidly reproduced 
pathological signatures of tauopathies already in early 
developmental stages in a time-dependent manner  [15] . 
Pathological misfolding of tau and hyperphosphoryla-
tion at several well-studied epitopes occurred within a 
few hours of development, and expression of late-stage 
pathological markers, such as AT8, rapidly progressed 
over time. Furthermore, NFTs with typical neuropatho-
logical features developed after 5 weeks. In addition, the 
fish displayed abnormal motoneuron function, leading to 
a retarded escape response. After a few days, they also 
developed significant neurodegeneration in the nervous 
system, and the new model allowed for the first time to 
image the degeneration of neurons live in an animal 
model by in vivo time-lapse microscopy. Strikingly, tau-
dependent neuronal cell loss was observed well before 
tangles formed. Thus, our findings may suggest that in 
contrast to the common opinion, tangles themselves are 
not neurotoxic but rather soluble tau oligomers. Alterna-
tively, elevated levels of tau monomers might also be tox-
ic, as they may trap cellular proteins and prevent them 
from executing their physiological functions.
 We also used the fish to identify and validate newly 
developed drugs, which may modify the pathologic hy-
perphosphorylation of tau. Hyperphosphorylation is be-
lieved to be a key initiator of detachment of normal tau 
from microtubules and subsequent oligomerization and 
aggregation. Preventing hyperphosphorylation by kinase 
inhibitors could slow further progression of pathology 
and thus be an efficient treatment option for AD and 
FTD  [16] . These inhibitors can be developed on a large 
scale by structure-based design  [17] , but this approach 
requires in vivo validation in cell culture and animal 
models. We validated two newly identified inhibitors of 
GSK3, a major kinase in tau phosphorylation  [18] . Inter-
estingly, one compound was highly active in preventing 
abnormal tau phosphorylation, while the other was com-
pletely inactive in fish, though equally potent in cell cul-
ture. The inactivity of one of the inhibitors could be due 
to low penetration through the developing blood-brain 
barrier or rapid degradation or metabolism of the com-
pound. This result illustrates the usefulness of the fish 
model as an effective in vivo screening tool to quickly and 
directly identify promising compounds and eliminate 
substances without reasonable in vivo activity early in the 
screening process. In addition, the tauopathy-like pheno-
types of the transgenic zebrafish may also allow perform-
ing unbiased large-scale compound screens to identify 
new drug targets and new compounds capable not only 
of reducing tau hyperphosphorylation, but also of restor-
ing axonal transport deficits and preventing synapse dys-
function as well as neuronal cell death.
 Since the versatility of the Gal4/UAS-based vector sys-
tem also allows to quickly subclone and express other 
proteins associated with neurodegenerative disease, the 
advantages of the fish system may now also be used to 
study related disease, such as Parkinson disease or the 
tau-negative cases of FTD.
 Taken together, transgenic zebrafish could be a prom-
ising tool to further elucidate the early pathological pro-
cesses leading synaptic dysfunction in neurodegenerative 
diseases and also to streamline pharmacological screen-
ing for new and effective drugs.
 Acknowledgements 
 This work was supported by grants from the Deutsche For-
schungsgemeinschaft (SFB 596 to B.S. and C.H.; the Center for 
Integrated Protein Science, to C.H. and B.S., and the Leibniz 
Award, to C.H.), Elitenetzwerk Bayern and Universität Bayern (to 
D.P.), and from the European Community’s Seventh Framework 
Programme (FP7/2007-2013) under grant agreement No. 200611 
(MEMOSAD, to C.H., B.S., and D.P.). C.H. is supported by a ‘Re-
search Professorship’ of the LMU.
 
 References  1 Haass C, Selkoe DJ: Soluble protein oligo-
mers in neurodegeneration: lessons from the 
Alzheimer’s amyloid beta-peptide. Nat Rev 
Mol Cell Biol 2007; 8: 101–112. 
 2 Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan 
M, Wisniewski HM, Binder LI: Abnormal 
phosphorylation of the microtubule-associ-
ated protein tau (tau) in Alzheimer cytoskel-
etal pathology. Proc Natl Acad Sci USA 1986; 
 83: 4913–4917. 
 3 Kosik KS, Joachim CL, Selkoe DJ: Microtu-
bule-associated protein tau (tau) is a major 
antigenic component of paired helical fila-
ments in Alzheimer disease. Proc Natl Acad 
Sci USA 1986; 83: 4044–4048. 
 4 Braak H, Braak E: Neuropathological stage-
ing of Alzheimer-related changes. Acta Neu-
ropathol 1991; 82: 239–259. 
 Paquet/Schmid/Haass Neurodegenerative Dis 2010;7:99–102102
 5 Santacruz K, Lewis J, Spires T, Paulson J, Ko-
tilinek L, Ingelsson M, Guimaraes A, DeTure 
M, Ramsden M, McGowan E, Forster C, Yue 
M, Orne J, Janus C, Mariash A, Kuskowski 
M, Hyman B, Hutton M, Ashe KH: Tau sup-
pression in a neurodegenerative mouse mod-
el improves memory function. Science 2005; 
 309: 476–481. 
 6 Hutton M, Lendon CL, Rizzu P, Baker M, 
Froelich S, Houlden H, Pickering-Brown S, 
Chakraverty S, Isaacs A, Grover A, Hackett 
J, Adamson J, Lincoln S, Dickson D, Davies 
P, Petersen RC, Stevens M, de Graaff E, 
Wauters E, van Baren J, Hillebrand M, Joosse 
M, Kwon JM, Nowotny P, Che LK, Norton J, 
Morris JC, Reed LA, Trojanowski J, Basun H, 
Lannfelt L, Neystat M, Fahn S, Dark F, Tan-
nenberg T, Dodd PR, Hayward N, Kwok JB, 
Schofield PR, Andreadis A, Snowden J, Crau-
furd D, Neary D, Owen F, Oostra BA, Hardy 
J, Goate A, van Swieten J, Mann D, Lynch T, 
Heutink P: Association of missense and 5  -
splice-site mutations in tau with the inher-
ited dementia FTDP-17. Nature 1998; 393: 
 702–705. 
 7 Götz J, Deters N, Doldissen A, Bokhari L, Ke 
Y, Wiesner A, Schonrock N, Ittner L: A de-
cade of tau transgenic animal models and be-
yond. Brain Pathol 2007; 17: 91–103. 
 8 Götz J, Ittner L: Animal models of Alzhei-
mer’s disease and frontotemporal dementia. 
Nat Rev Neurosci 2008; 9: 532–544. 
 9 Rubinstein AL: Zebrafish: from disease 
modeling to drug discovery. Curr Opin Drug 
Discov Devel 2003; 6: 218–223. 
 10 Zon LI, Peterson RT: In vivo drug discovery 
in the zebrafish. Nat Rev Drug Discov 2005;  
 4: 35–44. 
 11 Tomasiewicz HG, Flaherty DB, Soria JP, 
Wood JG: Transgenic zebrafish model of 
neurodegeneration. J Neurosci Res 2002; 70: 
 734–745. 
 12 Bai Q, Garver JA, Hukriede NA, Burton EA: 
Generation of a transgenic zebrafish model 
of tauopathy using a novel promoter element 
derived from the zebrafish eno2 gene. Nucle-
ic Acids Res 2007; 35: 6501–6516. 
 13 Price DL, Sisodia SS, Borchelt DR: Genetic 
neurodegenerative diseases: the human ill-
ness and transgenic models. Science 1998; 
 282: 1079–1083. 
 14 Koster RW, Fraser SE: Tracing transgene ex-
pression in living zebrafish embryos. Dev 
Biol 2001; 233: 329–346. 
 15 Paquet D, Bhat R, Sydow A, Mandelkow E, 
Berg S, Hellberg S, Fälting J, Distel M, Köster 
RW, Schmid B, Haass C: A zebrafish model 
of tauopathy allows in vivo imaging of neu-
ronal cell death and drug evaluation. J Clin 
Invest 2009; 119: 1382–1395. 
 16 Mazanetz MP, Fischer PM: Untangling tau 
hyperphosphorylation in drug design for 
neurodegenerative diseases. Nat Rev Drug 
Discov 2007; 6: 464–479. 
 17 Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, 
Nilsson Y, Radesater AC, Jerning E, Markgren 
PO, Borgegard T, Nylof M, Gimenez-Cassina 
A, Hernandez F, Lucas JJ, Diaz-Nido J, Avila 
J: Structural insights and biological effects of 
glycogen synthase kinase 3-specific inhibi-
tor ar-a014418. J Biol Chem 2003; 278: 45937–
45945. 
 18 Doble BW, Woodgett JR: Gsk-3: tricks of the 
trade for a multi-tasking kinase. J Cell Sci 
2003; 116: 1175–1186. 
 
